Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention
- PMID: 15136493
- DOI: 10.1161/01.CIR.0000129773.70647.94
Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention
Abstract
Background: High levels of the soluble fragment of CD40 ligand (sCD40L) have previously been associated with adverse cardiovascular outcomes. CD40L-CD40 interaction has been linked to the pathogenesis of atherothrombotic complications in cardiovascular disease (CVD). We sought to determine whether a "package of care" of intensified multifactorial cardiovascular risk intervention could reduce indices of platelet activation, inflammation, and coagulation in diabetes and whether patients with overt CVD would derive similar benefit compared with those without.
Methods and results: We measured plasma sCD40L, soluble P-selectin (sP-sel, an index of platelet activation), interleukin-6 (IL-6, a proinflammatory cytokine), and tissue factor (TF, an initiator of coagulation) in 97 patients with diabetes mellitus (41 with and 56 without overt CVD) and 39 comparable healthy control subjects. Thirty-six patients with and 32 without overt CVD then participated in a package of care of cardiovascular risk intervention over a period of 1 year. Plasma levels of sCD40L (P<0.001), sP-sel (P<0.001), IL-6 (P=0.001), and TF (P<0.001) were higher in patients with diabetes than in control subjects, with TF levels highest in patients with overt CVD. Multifactorial intervention was associated with significant reductions in sCD40L in both patient groups (both P<0.001), but reductions in sP-sel and TF were seen only in patients without overt CVD. There was no significant change in IL-6 levels in both patient groups.
Conclusions: Intensive multifactorial risk management can reduce high levels of sCD40L but can only partially correct abnormal platelet activation, inflammation, and coagulation in diabetes, particularly in patients with overt CVD.
Similar articles
-
Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease.Am J Cardiol. 2005 Nov 15;96(10):1365-9. doi: 10.1016/j.amjcard.2005.07.039. Epub 2005 Sep 19. Am J Cardiol. 2005. PMID: 16275179
-
Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.Circulation. 2005 Feb 1;111(4):412-9. doi: 10.1161/01.CIR.0000153810.81187.7D. Circulation. 2005. PMID: 15687128 Clinical Trial.
-
Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.Clin Ther. 2006 Jun;28(6):860-71. doi: 10.1016/j.clinthera.2006.06.010. Clin Ther. 2006. PMID: 16860169 Clinical Trial.
-
CD40 ligand: a novel target in the fight against cardiovascular disease.Ann Pharmacother. 2004 Sep;38(9):1500-8. doi: 10.1345/aph.1D611. Epub 2004 Jul 27. Ann Pharmacother. 2004. PMID: 15280513 Review.
-
The CD40-CD40L system in cardiovascular disease.Ann Med. 2011 Aug;43(5):331-40. doi: 10.3109/07853890.2010.546362. Epub 2011 Jan 18. Ann Med. 2011. PMID: 21244217 Review.
Cited by
-
State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.Curr Cardiovasc Risk Rep. 2015 Jan;9:4. doi: 10.1007/s12170-014-0430-5. Curr Cardiovasc Risk Rep. 2015. PMID: 25844111 Free PMC article.
-
Diabetes is a proinflammatory state: a translational perspective.Expert Rev Endocrinol Metab. 2010 Jan 1;5(1):19-28. doi: 10.1586/eem.09.44. Expert Rev Endocrinol Metab. 2010. PMID: 20204165 Free PMC article.
-
Interleukin-1β Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor.J Clin Med. 2019 Nov 26;8(12):2072. doi: 10.3390/jcm8122072. J Clin Med. 2019. PMID: 31779200 Free PMC article.
-
The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.J Diabetes Sci Technol. 2011 Mar 1;5(2):426-32. doi: 10.1177/193229681100500233. J Diabetes Sci Technol. 2011. PMID: 21527115 Free PMC article. Clinical Trial.
-
Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation.J Vasc Surg. 2007 Jun;45 Suppl A(Suppl A):A149-57. doi: 10.1016/j.jvs.2007.02.029. J Vasc Surg. 2007. PMID: 17544036 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous